Theratechnologies (THTX)
(Delayed Data from NSDQ)
$1.25 USD
0.00 (0.00%)
Updated May 31, 2024 03:59 PM ET
After-Market: $1.25 0.00 (0.00%) 6:20 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
THTX 1.25 0.00(0.00%)
Will THTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for THTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for THTX
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
THTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for THTX
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies to present Phase 1 data on Sudocetaxel Zendusortide at ASCO
Theratechnologies (THTX) Gets a Buy from JonesTrading
Theratechnologies Shareholders Elect Directors, Appoint Auditors
Theratechnologies Reports on its Annual Meeting of Shareholders